Publications

2018
MM and MGUS

  1. Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, Apperley JF, Pohlreich D, Browne PV, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland SO, Morris C, Garderet L, Kröger N. Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica. 2018 Mar;103(3):514-521. doi: 10.3324/haematol.2017.181339. Epub 2017 Dec 7. IF 9,090
  2. Coriu D, Dytfeld D, Niepel D, Spicka I, Markuljak I, Mihaylov G, Ostojic-Kolonic S, Fink L, Toka KS, Björklöf K. Real‑world multiple myeloma management practice patterns and outcomes in selected Central and Eastern European countries. Pol Arch Intern Med. 2018 Sep 28;128(9):500-511. doi: 10.20452/pamw.4305. Epub 2018 Jul 27. IF 2,658
  3. Dimopoulos M, Wang M, Maisnar V, Minarik J, Bensinger W, Mateos MV, Obreja M, Blaedel J, Moreau P. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018 Apr 4;11(1):49. doi: 10.1186/s13045-018-0583-7. IF 7,333
  4. Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson JE, Bourhis JH, Krejci M, Leleu X, Potter M, Blaise D, Koenecke C, Peschel C, Radocha J, Metzner B, Lenain P, Schäfer-Eckart K, Pohlreich D, Grasso M, Caillot D, Einsele H, Ladetto M, Schönland S, Kröger N. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. Biol Blood Marrow Transplant. 2018 Jul;24(7):1372-1378. doi: 10.1016/j.bbmt.2018.01.035. Epub 2018 Feb 3. IF 4,484
  5. Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018 Sep;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7. Epub 2018 Jul 23. Review. IF 10,023
  6. Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018 Feb;103(2):197-211. doi: 10.3324/haematol.2017.174573. Epub 2017 Dec 7. Review. IF 9,090
  7. Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M. Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961. IF 20,871
  8. Gregorová J, Vrábel D, Radová L, Gablo NA, Almaši M, Štork M, Slabý O, Pour L, Minařík J, Ševčíková S. MicroRNA Analysis for Extramedullary Multiple Myeloma Relapse. Klin Onkol. 2018 Spring;31(Supplementum1):148-150. Czech.
  9. Hájek R, Jarkovsky J, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Campioni M, DeCosta L, Treur M, Gonzalez-McQuire S, Bouwmeester W. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies. Clin Lymphoma Myeloma Leuk. 2018 Jun;18(6):e219-e240. doi: 10.1016/j.clml.2018.04.003. Epub 2018 Apr 17. IF 2,308
  10. Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, Hajek R, Groarke J, Lyon AR, Batty GN, Ro S, Huang M, Iskander KS, Lenihan D. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Adv. 2018 Jul 10;2(13):1633-1644. doi: 10.1182/bloodadvances.2017015545.
  11. Jelinek T, Bezdekova R, Zatopkova M, Burgos L, Simicek M, Sevcikova T, Paiva B, Hajek R. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J. 2017 Oct 20;7(10):e617. doi: 10.1038/bcj.2017.90. Review. Erratum in: Blood Cancer J. 2018 Jan 19;8(1):e621. IF 8,125
  12. Jelínek T, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Adamová D, Wróbel M, Mikula P, Jarkovský J, Diels J, Gatopoulou X, Veselá Š, Besson H, Brožová L, Ito T, Hájek R. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. Curr Med Res Opin. 2018 May;34(5):775-783. doi: 10.1080/03007995.2017.1410121. Epub 2018 Feb 15. IF 2,665
  13. Jungova A, Vokurka S, Schutzova M, Steinerova K, Mohammadova L, Karas M, Lysak D, Jindra P. Comparison of the autologous hematopoietic cell transplantation performed in tandem or in disease relapse in patients with multiple myeloma. Neoplasma. 2018 Jun 26. doi: 10.4149/neo_2018_170511N346. IF 10,023
  14. Jurczyszyn A, Davila J, Kortüm KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wiśniewska-Piąty K, Waszczuk-Gajda A, Crusoe E, Hajek R, Robak P, Raźny M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. Leuk Lymphoma. 2018 Jul 22:1-6. doi: 10.1080/10428194.2018.1480766. [Epub ahead of print] IF 2,644
  15. Leleu X, Masszi T, Bahlis NJ, Viterbo L, Baker B, Gimsing P, Maisnar V, Samoilova O, Rosiñol L, Langer C, Song K, Izumi T, Cleeland C, Berg D, Lin HM, Zhu Y, Skacel T, Moreau P, Richardson PG. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25134. [Epub ahead of print] IF 5,303
  16. Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2. Review. IF 10,023
  17. Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12. IF 79,260
  18. Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 28. IF 2,308
  19. Radocha J, Maisnar V, Pour L, Špička I, Minařík J, Szeligová L, Pavlíček P, Jungová A, Krejčí M, Pika T, Straub J, Brožová L, Stejskal L, Heindorfer A, Jindra P, Kessler P, Mikula P, Sýkora M, Wróbel M, Jarkovský J, Hájek R. Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. Cancer Med. 2018 Aug;7(8):4132-4145. doi: 10.1002/cam4.1620. Epub 2018 Jun 21. IF 3,202
  20. Raje N, Terpos E, Willenbacher W, Shimizu K, García-Sanz R, Durie B, Legieć W, Krejčí M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9. IF 36,421
  21. Sahebi F, Iacobelli S, Sbianchi G, Koster L, Blaise D, Reményi P, Russell NH, Ljungman P, Kobbe G, Apperley J, Trneny M, Krejci M, Wiktor-Jedrzejczak W, Sanchez JF, Schaap N, Isaksson C, Lenhoff S, Browne P, Scheid C, Wilson KMO, Yakoub-Agha I, Muñiz SG, Schönland S, Morris C, Garderet L, Kröger N. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. Biol Blood Marrow Transplant. 2018 May;24(5):930-936. doi: 10.1016/j.bbmt.2018.01.006. Epub 2018 Jan 12. IF 4,484
  22. San-Miguel JF, Echeveste Gutierrez MA, Špicka I, Mateos MV, Song K, Craig MD, Bladé J, Hájek R, Chen C, Di Bacco A, Estevam J, Gupta N, Byrne C, Lu V, van de Velde H, Lonial S. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica. 2018 Sep;103(9):1518-1526. doi: 10.3324/haematol.2017.185991. Epub 2018 Jun 28. IF 9,090
  23. Sedlarikova L, Bollova B, Radova L, Brozova L, Jarkovsky J, Almasi M, Penka M, Kuglík P, Sandecká V, Stork M, Pour L, Sevcikova S. Circulating exosomal long noncoding RNA PRINS-First findings in monoclonal gammopathies. Hematol Oncol. 2018 Aug 24. doi: 10.1002/hon.2554. [Epub ahead of print] IF 7,333
  24. Smetana J, Oppelt J, Štork M, Pour L, Kuglík P. Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse. Mol Cytogenet. 2018 Jan 18;11:7. doi: 10.1186/s13039-018-0357-5. eCollection 2018. IF 1,167
  25. Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Sep 20. pii: haematol.2018.194118. doi: 10.3324/haematol.2018.194118. [Epub ahead of print] IF 9,090
  26. Steiner N, Hajek R, Sevcikova S, Borjan B, Untergasser G, Göbel G, Gunsilius E. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma. Anticancer Res. 2018 Sep;38(9):5087-5092. doi: 10.21873/anticanres.12828. IF 1,865
  27. Steiner N, Müller U, Hajek R, Sevcikova S, Borjan B, Jöhrer K, Göbel G, Pircher A, Gunsilius E. The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. PLoS One. 2018 Aug 10;13(8):e0202045. doi: 10.1371/journal.pone.0202045. eCollection 2018. IF 2,766
  28. Stork M, Sevcikova S, Adam Z, Krejci M, Sandecka V, Kral Z, Brozova L, Velichova R, Pour L. Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients. Neoplasma. 2018;65(4):585-591. doi: 10.4149/neo_2018_170519N363. IF 10,023
  29. Yong K, Gonzalez-McQuire S, Szabo Z, Schoen P, Hajek R. The start of a new wave: Developments in proteasome inhibition in multiple myeloma. Eur J Haematol. 2018 Mar 30. doi: 10.1111/ejh.13071. [Epub ahead of print] Review. IF 2,595
  30. Vrábel D, Pour L, Ševčíková S. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Rev. 2018 Nov 23. pii: S0268-960X(18)30044-4. doi: 10.1016/j.blre.2018.11.003. [Epub ahead of print] Review. IF 6,6
  31. Zavrelova A, Paterova P, Gabalec F, Zak P, Radocha J. Ciprofloxacin prophylaxis during autologous stem cell transplantation for multiple myeloma in patients with a high rate of fluoroquinolone-resistant gram-negative bacteria colonization. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Sep 7. doi: 10.5507/bp.2018.047. [Epub ahead of print] IF 1,087

Other projects 2018

  1. Adam Z, Chovancová Z, Nová M, Fabian P, Řehák Z, Koukalová R, Slávik M, Pour L, Krejčí M, Čermák A, Král Z, Mayer J. Remission of the disease associated/related with immunoglobulin IgG4 accompanied by multiple lymphadenopathy after treatment with rituximab and dexamethasone: a case report. Vnitr Lek. 2018 Spring;64(3):290-299. Czech.
  2. Adam Z, Ozábalová E, Němec P, Bedáňová H, Kuman M, Krejčí J, Špinarová L, Žampachová V, Čermáková Z, Pour L, Krejčí M, Sanecká V, Štork M, Pika T, Straub J, Adamová D, Stavařová Y, Král Z, Mayer J. Heart transplantation and follow-up treatment with AL-amyloidosis in 5 patients. Vnitr Lek. 2018 Spring;64(4):441-449. Czech.
  3. Adam Z, Skřičková J, Krtička M, Řehák Z, Koukalová R, Šprláková A, Krejčí M, Pour L, Adamová Z, Pourová E, Král Z. Remission of steroid-resistant Stills disease treated with anakinra, evidenced by FDG-PET/CT examination: case report. Vnitr Lek. Winter 2018;63(12):987-997. Czech.
  4. Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5. Review. IF 10,698
  5. Flodrova P, Flodr P, Pika T, Vymetal J, Holub D, Dzubak P, Hajduch M, Scudla V. Cardiac amyloidosis: from clinical suspicion to morphological diagnosis. Pathology. 2018 Apr;50(3):261-268. doi: 10.1016/j.pathol.2017.10.012. Epub 2018 Feb 12. Review. IF 3,068
  6. Chyra Kufova Z, Sevcikova T, Januska J, Vojta P, Boday A, Vanickova P, Filipova J, Growkova K, Jelinek T, Hajduch M, Hajek R. Newly designed 11-gene panel reveals first case of hereditary amyloidosis captured by massive parallel sequencing. J Clin Pathol. 2018 Aug;71(8):687-694. doi: 10.1136/jclinpath-2017-204978. Epub 2018 Feb 17. IF 2,894
  7. Pika T, Hegenbart U, Flodrova P, Maier B, Kimmich C, Schönland SO. First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival. Blood. 2018 Jan 18;131(3):368-371. doi: 10.1182/blood-2017-09-806463. Epub 2017 Nov 27. IF 15,132

Publications 2017
MM and MGUS

  1. Adam Z, Straub J, Krejčí M, Pour L, Brančíková D, Ostřížková L, Sandecká V, Štork M. Osteoprotective therapy with bisphosphonates or denosumab in patients with multiple myeloma: benefit and risks. Vnitr Lek. 2017 Summer;63(5):311-321. Czech.
  2. Almasi M, Sevcikova S, Penka M, Krejci M, Adam Z, Vrublova P, Jelínek T, Hájek R. Biobanking - the First Step to Successful Liquid Biopsy Experiments. Klin Onkol. 2017 Summer;30(Supplementum2):9-12. doi: 10.14735/amko20172S9.
  3. Bezdekova R, Penka M, Hájek R, Rihova L. Circulating Plasma Cells in Monoclonal Gammopathies. Klin Onkol. 2017 Summer;30(Supplementum2):29-34. doi: 10.14735/amko20172S29.
  4. Brozova L, Jarkovský J, Pour L, Minárik J, Jungová A, Gregora E, Spicka I, Maisnar V, Hájek R. Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies. Klin Onkol. 2017 Summer;30(Supplementum2):51-59. doi: doi: 10.14735/amko20172S51.
  5. Brozova L, Schwarz D, Snabl I, Kalina J, Pavlickova B, Komenda M, Jarkovský J, Němec P, Horinek D, Stefanikova Z, Pour L, Hájek R, Maisnar V. Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation. Klin Onkol. 2017 Summer;30(Supplementum2):43-50. doi: 10.14735/amko20172S43.
  6. Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA. IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol. 2017 Aug;92(8):746-751. doi: 10.1002/ajh.24753. Epub 2017 May 26. IF 5,275
  7. Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23. IF 47,831
  8. Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Ro S, Aggarwal S, Moreau P, Palumbo A. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017 Apr 21;7(4):e554. doi: 10.1038/bcj.2017.31. IF 6,126
  9. Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Palumbo A, Obreja M, Aggarwal S, Moreau P. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017 May;177(3):404-413. doi: 10.1111/bjh.14549. Epub 2017 Feb 17. IF 5,670
  10. Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017 Sep;178(6):896-905. doi: 10.1111/bjh.14787. Epub 2017 Jul 5. IF 5,670
  11. Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia. 2017 Aug;31(8):1727-1734. doi: 10.1038/leu.2016.381. Epub 2016 Dec 23. IF 11,702
  12. Grzasko N, Hajek R, Hus M, Chocholska S, Morawska M, Giannopoulos K, Czarnocki K, Druzd-Sitek A, Pienkowska-Grela B, Rygier J, Usnarska-Zubkiewicz L, Dytfeld D, Kubicki T, Jurczyszyn A, Korpysz M, Dmoszynska A. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. Leuk Lymphoma. 2017 Sep;58(9):1-15. doi: 0.1080/10428194.2016.1272684. Epub 2017 Jan 16. IF 2,755
  13. Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017 Jan;31(1):107-114. doi: 10.1038/leu.2016.176 IF 11,702
  14. Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.122. [Epub ahead of print] IF 11,702
  15. Chng WJ, Goldschmidt H, Dimopoulos MA, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hájek R. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017 Jun;31(6):1368-1374. doi: 10.1038/leu.2016.390. Epub 2016 Dec 27. IF 11,702
  16. Jelínek T, Kořístka M, Čermáková Z, Hájek R. Daratumumab - Hope for Myeloma Patients, a Challenge for Clinical Laboratories. Klin Onkol. Winter 2017;30(1):13-19. doi: 10.14735/amko201713. Czech.
  17. Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol. 2017 Aug;178(4):571-582. doi: 10.1111/bjh.14733. Epub 2017 May 9. IF 5,670
  18. Lambert L, Ourednicek P, Meckova Z, Gavelli G, Straub J, Spicka I. Whole-body low-dose computed tomography in multiple myeloma staging: Superior diagnostic performance in the detection of bone lesions, vertebral compression fractures, rib fractures and extraskeletal findings compared to radiography with similar radiation exposure. Oncol Lett. 2017 Apr;13(4):2490-2494. doi: 10.3892/ol.2017.5723. Epub 2017 Feb 13. IF 1,390
  19. Ludwig H, Dimopoulos MA, Moreau P, Chng WJ, Goldschmidt H, Hájek R, Facon T, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Palumbo A, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Joshua D. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leuk Lymphoma. 2017 Oct;58(10):2501-2504. doi: 10.1080/10428194.2017.1298755. Epub 2017 Mar 17. IF 2,755
  20. Maluskova D, Svobodová I, Kucerova M, Brozova L, Muzik J, Jarkovský J, Hájek R, Maisnar V, Dusek L. Epidemiology of Multiple Myeloma in the Czech Republic. Klin Onkol. 2017 Summer;30(Supplementum2):35-42. doi: 10.14735/amko20172S35.
  21. Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica. 2017 Oct;102(10):1767-1775. doi: 10.3324/haematol.2017.170118. Epub 2017 Jul 27. IF 7,702
  22. Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica. 2017 Sep;102(9):1617-1625. doi: 10.3324/haematol.2017.163766. Epub 2017 May 26. IF 7,702
  23. Minarik J, Novak M, Flodr P, Balcarkova J, Mlynarcikova M, Krhovska P, Pika T, Pikalova Z, Bacovsky J, Scudla V. CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy. Eur J Haematol. 2017 Aug;99(2):186-189. doi: 10.1111/ejh.12902. Epub 2017 Jun 6. IF 2,653
  24. Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, Hájek R, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Dimopoulos MA. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017 Jan;31(1):115-122. doi: 10.1038/leu.2016.186. IF 11,702
  25. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61. doi: 10.1093/annonc/mdx096. IF 11,855
  26. Rihova L, Vsianska P, Bezdekova R, Kralova R, Penka M, Krejci M, Pour L, Hájek R. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry. Klin Onkol. 2017 Summer;30(Supplementum2):21-28. doi: 10.14735/amko20172S21.
  27. Sandecká V, Hájek R, Pour L, Špička I, Ščudla V, Gregora E, Radocha J, Walterová L, Kessler P, Zahradová L, Adamová D, Valentova K, Vonke I, Obernauerová J, Starostka D, Wróbel M, Brožová L, Jarkovský J, Mikulášová A, Říhová L, Ševčíková S, Straub J, Minařík J, Adam Z, Krejčí M, Král Z, Maisnar V; Czech Myeloma Group. A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. Eur J Haematol. 2017 Jul;99(1):80-90. doi: 10.1111/ejh.12894. Epub 2017 May 11. IF 2,653
  28. Sedlarikova L, Gromesova B, Kubaczkova V, Radova L, Filipova J, Jarkovsky J, Brozova L, Velichova R, Almasi M, Penka M, Bezdekova R, Stork M, Adam Z, Pour L, Krejci M, Kuglík P, Hajek R, Sevcikova S. Deregulated expression of long non-coding RNA UCA1 in multiple myeloma. Eur J Haematol. 2017 Sep;99(3):223-233. doi: 10.1111/ejh.12908. Epub 2017 Jun 29. IF 2,653
  29. Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017 Jul;178(1):61-71. doi: 10.1111/bjh.14637. Epub 2017 Apr 6. IF 5,670
  30. Simicek M, Growkova K, Hájek R. CRISPR in Research and Treatment of Multiple Myeloma. Klin Onkol. 2017 Summer;30(Supplementum2):68-74. doi: 10.14735/amko20172S68.
  31. Schneiderova P, Pika T, Gajdos P, Fillerova R, Kromer P, Kudelka M, Minarik J, Papajik T, Scudla V, Kriegova E. Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma. Oncotarget. 2016 Aug 12. doi: 10.18632/oncotarget.11242. IF 6,359
  32. Steiner N, Borjan B, Hajek R, Jöhrer K, Göbel G, Willenbacher W, Kern J, Gunsilius E, Untergasser G. Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma. Oncotarget. 2017 Apr 21;8(34):56243-56254. doi: 10.18632/oncotarget.17353. IF 5,168
  33. Steiner N, Hajek R, Sevcikova S, Borjan B, Jöhrer K, Göbel G, Untergasser G, Gunsilius E. High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. PLoS One. 2017 Jul 20;12(7):e0181487. doi: 10.1371/journal.pone.0181487. eCollection 2017. IF 2,806
  34. Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J Clin Oncol. 2016 Sep 6. pii: JCO669648. [Epub ahead of print] IF 24,008
  35. Ševčíková T, Growková K, Kufová Z, Filipová J, Vrublová P, Jelínek T, Kořístek Z, Kryukov F, Kryukova E, Hájek R. Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies. J Clin Pathol. 2017 Oct;70(10):847-853. doi: 10.1136/jclinpath-2017-204329. Epub 2017 Mar 30. IF 2,687
  36. Thomsen H, Campo C, Weinhold N, da Silva Filho MI, Pour L, Gregora E, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, Hajek R, Goldschmidt H, Hemminki K, Försti A. Genomewide association study on monoclonal gammopathy of unknown significance (MGUS). Eur J Haematol. 2017 Jul;99(1):70-79. doi: 10.1111/ejh.12892. Epub 2017 May 24. IF 2,653
  37. Všianská P, Bezděková R, Kryukov F, Almáši M, Pour L, Penka M, Hájek R, Říhová L. Activity of aldehyde dehydrogenase in B-cell and plasma cell subsets of monoclonal gammopathy patients and healthy donors. Eur J Haematol. 2017 Jan;98(1):19-25. doi: 10.1111/ejh.12779. IF 2,653
  38. Zatopkova M, Filipová J, Jelínek T, Vojta P, Sevcikova T, Simicek M, Rihova L, Bezdekova R, Growkova K, Kufová Z, Smejkalová J, Hajdúch M, Pour L, Minárik J, Jungová A, Maisnar V, Kryukov F, Hájek R. Whole Exome Sequencing of Aberrant Plasma Cells in a Patient with Multiple Myeloma Minimal Residual Disease. Klin Onkol. 2017 Summer;30(Supplementum2):75-80. doi: 10.14735/amko20172S75.

Other projects 2017

  1. Filipova J, Rihova L, Vsianska P, Kufova Z, Kryukova E, Kryukov F, Hajek R. Flow cytometry in immunoglobulin light chain amyloidosis: Short review. Leuk Res. 2015 Jul 13. pii: S0145-2126(15)30345-3. doi: 10.1016/j.leukres.2015.07.002. [Epub ahead of print] Review. IF 2,692
  2. Growkova K, Kufová Z, Sevcikova T, Filipová J, Kascak M, Jelínek T, Grosicki S, Barchnicka A, Roziaková Ľ, Mistrík M, Simicek M, Hájek R. Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring. Klin Onkol. 2017 Summer;30(Supplementum2):81-91. doi: 10.14735/amko20172S81.
  3. Growková K, Kryukova E, Kufová Z, Filipová J, Ševčíková T, Říhová L, Kaščák M, Kryukov F, Hájek R. Waldenström's Macroglobulinemia: two malignant clones in a monoclonal disease? Molecular background and clinical reflection. Eur J Haematol. 2017 Sep 8. doi: 10.1111/ejh.12959. [Epub ahead of print] Review. IF 2,653
  4. Jelinek T, Kryukova E, Kufova Z, Kryukov F, Hajek R. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. Hematol Oncol. 2016 Sep 20. doi: 10.1002/hon.2351. [Epub ahead of print] Review. IF 3,084
  5. Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology. 2017 Nov;152(3):357-371. doi: 10.1111/imm.12788. Epub 2017 Aug 4. Review. IF 3,701
  6. Karafiatova L, Pika T. Amyloid cardiomyopathy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Jun;161(2):117-127. doi: 10.5507/bp.2017.001. Epub 2017 Feb 1. IF 0,894
  7. Kubaczková V, Sedlarikova L, Bollová B, Sandecká V, Stork M, Pour L, Sevcikova S. Liquid Biopsies - the Clinics and the Molecules. Klin Onkol. 2017 Summer;30(Supplementum2):13-20. doi: 10.14735/amko20172S13.
  8. Kubaczkova V, Vrabel D, Sedlarikova L, Besse L, Sevcikova S. Cell-free DNA - Minimally invasive marker of hematological malignancies. Eur J Haematol. 2017 Oct;99(4):291-299. doi: 10.1111/ejh.12925. Epub 2017 Aug 3. Review. IF 2,653
  9. Kufová Z, Sevcikova T, Growkova K, Vojta P, Filipová J, Adam Z, Pour L, Penka M, Rysava R, Němec P, Brozova L, Vychytilova P, Jurczyszyn A, Grosicki S, Barchnicka A, Hajdúch M, Simicek M, Hájek R. Biomarkers in Immunoglobulin Light Chain Amyloidosis. Klin Onkol. 2017 Summer;30(Supplementum2):60-67. doi: 10.14735/amko20172S60.

 

Publication 2016

MM a MGUS

  1. Adam Z, Pourová E, Pour L, Michalková E, Krejčí M, Koukalová R, Řehák Z, Vaníček J, Nebeský T, Petrášová H, Ševčíková S, Mašek M, Král Z, Čermák A. The patient complains of spinal pain or fatigue and weakness. How do I recognize whether their cause is spondylarthrosis, the patients age or multiple myeloma? Vnitr Lek. 2016 Feb;62(2):114-24. Czech.
  2. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 Sep 1;128(9):1174-80. doi: 10.1182/blood-2016-03-707596. IF 10,452
  3. Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, Jelinek T, Pour L, Adam Z, Kuglik P, Krejci M, Hajek R, Sevcikova S. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol. 2016 Jul;97(1):93-100. doi: 10.1111/ejh.12688.IF 2,414
  4. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. IF 24,69
  5. Jelinek T, Hajek R. Monoclonal antibodies - A new era in the treatment of multiple myeloma. Monoclonal antibodies - A new era in the treatment of multiple myeloma. Blood Rev. 2016 Mar;30(2):101-10. doi: 10.1016/j.blre.2015.08.004.IF 5,451
  6. Jurczyszyn A, Olszewska-Szopa M, Hungria V, Crusoe E, Pika T, Delforge M, Leleu X, Rasche L, Nooka AK, Druzd-Sitek A, Walewski J, Davila J, Caers J, Maisnar V, Gertz M, Gentile M, Fantl D, Mele G, Vesole DH, Yee AJ, Shustik C, Lentzsch S, Zweegman S, Gozzetti A, Skotnicki AB, Castillo JJ. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016 Sep;57(9):2071-6. doi: 10.3109/10428194.2015.1128542. IF 2,891
  7. Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016 Jun;91(6):575-80. doi: 10.1002/ajh.24351. IF 3,798
  8. Kryukov F, Nemec P, Radova L, Kryukova E, Okubote S, Minarik J, Stefanikova Z, Pour L, Hajek R. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. J Transl Med. 2016 May 28;14(1):150. doi: 10.1186/s12967-016-0906-9. IF 3,93
  9. Kryukova E, Kryukov F, Hajek R. Centrosome amplification and clonal evolution in multiple myeloma: Short review. Crit Rev Oncol Hematol. 2016 Feb;98:116-21. doi: 10.1016/j.critrevonc.2015.10.019. Review. IF 4,027
  10. Leleu X, Terpos E, Sanz RG, Cooney J, O'Gorman P, Minarik J, Greil R, Williams C, Gray D, Szabo Z. An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). Am J Hematol. 2016 Aug;91(8):806-11. doi: 10.1002/ajh.24416. IF 3,798
  11. Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016 Mar 3;127(9):1102-8. doi: 10.1182/blood-2015-08-662627. IF 10,452
  12. Mikulasova A, Smetana J, Wayhelova M, Janyskova H, Sandecka V, Kufova Z, Almasi M, Jarkovsky J, Gregora E, Kessler P, Wrobel M, Walker BA, Wardell CP, Morgan GJ, Hajek R, Kuglik P. Genome-wide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance. Eur J Haematol. 2016 Dec;97(6):568-575. doi: 10.1111/ejh.12774. IF 2,414
  13. Minarik J, Krhovska P, Hrbek J, Pika T, Bacovsky J, Herman M, Scudla V. Prospective comparison of conventional radiography, low-dose computed tomography and magnetic resonance imaging in monoclonal gammopathies. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Jun;160(2):305-9. doi: 10.5507/bp.2015.064. IF 0,924
  14. Minarik J, Hermanova Z, Petrova P, Hrbek J, Zapletalova J, Krhovska P, Flodr P, Pika T, Bacovsky J, Flodrova P, Herman M, Scudla V. Prospective study of signalling pathways in myeloma bone disease with regard to activity of the disease, extent of skeletal involvement and correlation to bone turnover markers. Eur J Haematol. 2016 Aug;97(2):201-7. doi: 10.1111/ejh.12708. IF 2,414
  15. Mlynarcikova M, Balcarkova J, Mickova P, Scudla V, Pika T, Bacovsky J, Minarik J, Janousova E, Jarosova M. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse. Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):358-65. doi: 10.1016/j.clml.2016.02.038. IF 2,316
  16. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282. IF 55,873
  17. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Xiu L, Cakana A, Parekh T, San-Miguel JF. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016 Jul 1;122(13):2050-6. doi: 10.1002/cncr.30026. IF 4,889
  18. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. IF 55,873
  19. Radocha J, Pour L, Pika T, Maisnar V, Špička I, Gregora E, Krejčí M, Minařík J, Machálková K, Straub J, Pavlíček P, Hájek R, Žák P. Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. Eur J Haematol. 2016 Feb;96(2):119-27. doi: 10.1111/ejh.12556. IF 2,414
  20. Scudla V, Lochman P, Pika T, Minarik J, Zapletalova J, Bacovsky J. Relationship of differences in immunoglobulin heavy/light chain pairs (HevyliteTM), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar;160(1):84-93. doi: 10.5507/bp.2015.032. IF 0,924
  21. Ščudla V, Balcárková J, Lochman P, Vincová M, Pika T, Minařík J, Zapletalová J, Jarošová M. Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System]. Vnitr Lek. 2016 Apr;62(4):269-80. Czech.
  22. Štork M, Krejčí M, Sandecká V, Král Z, Pour L. Use of new drugs within primary therapy of multiple myeloma. Vnitr Lek. 2016 Spring;62(5):413-22. Czech.
  23. Thangavadivel S, Zelle-Rieser C, Olivier A, Postert B, Untergasser G, Kern J, Brunner A, Gunsilius E, Biedermann R, Hajek R, Pour L, Willenbacher W, Greil R, Jöhrer K. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. Oncotarget. 2016 Nov 29;7(48):78605-78618 IF 6,359

Other projects 2016

  1. Adam Z, Mašlaň J, Křen L, Kodet R, Koukalová R, Řehák Z, Červinek L, Pour L, Krejčí M, Sandecká V, Král Z, Mayer J. Sinus histiocytosis with massive lymphadenopathy: FDG-PET/CT documented partial remission after treatment with 2-chlorodeoxyadenosine. Vnitr Lek. 2016 Summer;62(6):491-9. Czech.
  2. Adam Z, Szturz P, Krejčí M, Koukalová R, Michalková E, Řehák Z, Pourová E, Pour L, Volfová P, Sandecká V, Čermáková Z, Křen L, Sokol F, Hanke I, Penka I, Petrášová H, Ševčíková S, Král Z, Mayer J. Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature. Vnitr Lek. 2016 Apr;62(4):287-98. Review. Czech.
  3. Adam Z, Pour L, Krejčí M, Ševčíková S, Pourová E, Ševčíková E, Král Z, Mayer J. Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience. Vnitr Lek. 2016 Jan;62(1):25-39. Review. Czech.
  4. Adam Z, Šedivá A, Koukalová R, Řehák Z, Petrášová H, Szturz P, Adamová Z, Vetešníková E, Pour L, Krejčí M, Sandecká V, Pourová E, Čermáková Z, Ševčíková S, Král Z, Mayer J. Schnitzlers Syndrome Differential diagnostics, an overview of therapeutic options and description of 5 cases treated with anakinra. Vnitr Lek. 2016 Fall;62(9):713-727. Czech.
  5. Fikrle M, Palecek T, Masek M, Kuchynka P, Straub J, Spicka I, Rysava R, Linhart A. The diagnostic performance of cardiac magnetic resonance in detection of myocardial involvement in AL amyloidosis. Clin Physiol Funct Imaging. 2016 May;36(3):218-24. doi: 10.1111/cpf.12216. IF 1,376
  6. Gromesová B, Kubaczková V, Bollová B, Sedlaříková L, Ševčíková S. Potential of Long Non- coding RNA Molecules in Diagnosis of Tumors. Klin Onkol. 2016;29(1):20-8. Review. Czech.
  7. Jelinek T, Kufova Z, Hajek R. Immunomodulatory drugs in AL amyloidosis. Crit Rev Oncol Hematol. 2016 Mar;99:249-60. doi: 10.1016/j.critrevonc.2016.01.004. Review. IF 4,027
  8. Kryukov F, Kryukova E, Brozova L, Kufova Z, Filipova J, Growkova K, Sevcikova T, Jarkovsky J, Hajek R. Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. Gene. 2016 Oct 15;591(2):490-8. doi: 10.1016/j.gene.2016.06.017. IF 2,138
  9. Kutálková K, Sedlaříková L, Adam Z, Ševčíková S. Gene mutations connected to Waldenstöm macroglobulinemia. Vnitr Lek. 2016 Jan;62(1):40-3. Review. Czech.

 

Older publications (2012 - 2015)

Older publications (2006 - 2011)

Older publications (1995 - 2005)